Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Pacific Biosciences of California(PACB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PACB
09/28/2026: PACB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Pacific Biosciences of California is a specialized life sciences company known for its high-fidelity, long-read DNA sequencing technology. Its primary strength lies in its ability to provide high-accuracy genomic data, which is essential for advanced research applications. The company's main growth narrative centers on the adoption of its Revio sequencing system and expanding into clinical markets. However, investors must monitor risks related to high cash burn, competitive pressure from dominant short-read sequencing incumbents, and the capital-intensive nature of its product line. The stock may best suit growth-oriented investors with a high risk tolerance who are looking for exposure to potential breakthroughs in personalized medicine and genomics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth sector with significant R&D focus and potential for transformative market disruption. |
| Momentum investor | Mixed fit | Momentum is highly conditional on product adoption cycles and positive sentiment, requiring an active upturn signal. |
| Value investor | Weak fit | Current negative earnings and high valuation multiples relative to historical revenue make it a poor fit for traditional value criteria. |
| Dividend investor | Weak fit | The company does not pay a dividend, as it is in a growth phase prioritizing capital reinvestment. |
| Low-risk investor | Weak fit | High volatility and the risks associated with hardware adoption make this an unsuitable choice for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on industry sentiment and quarterly performance updates. |
| Valuation risk | Medium / high | Growth expectations are often priced into the stock, leaving little room for error in quarterly results. |
| Competition risk (Illumina-led short-read dominance) | High | Aggressive pricing and large installed bases of major incumbents create significant barriers to entry. |
| Business quality | Medium | The company has proprietary technology but lacks the long-term stable cash flows of more established industry peers. |
| Dividend income | Low / none | There is no dividend income stream for investors, limiting its appeal to income-focused portfolios. |
| Execution risk | Medium / high | The success of the firm hinges on flawless execution of hardware rollout and reagent consumable growth targets. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -80.11% | Avg. Invested days 15 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 531.52M USD | Price to earnings Ratio - | 1Y Target Price 2.16 |
Price to earnings Ratio - | 1Y Target Price 2.16 | ||
Volume (30-day avg) 6.9M shares | Beta 2.31 | 52 Weeks Range 1.07 - 2.73 | Updated Date 09/29/2026 |
52 Weeks Range 1.07 - 2.73 | Updated Date 09/29/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Sequencing Instruments | Sale of Revio and Onso platforms to genomic research centers and clinical facilities. | The company sells expensive high-tech machines, which is a one-time capital sale. |
| Consumables and Service | Ongoing sales of proprietary reagents, flow cells, and maintenance support contracts. | This is the 'razor-and-blade' business model where recurring revenue follows the sale of machines. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 904.42M | Price to Sales(TTM) 3.34 |
Enterprise Value 904.42M | Price to Sales(TTM) 3.34 | ||
Enterprise Value to Revenue 5.68 | Enterprise Value to EBITDA 140.79 | Shares Outstanding 310.83M | Shares Floating 304.01M |
Shares Outstanding 310.83M | Shares Floating 304.01M | ||
Percent Insiders 8.91 | Percent Institutions 55.52 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Pacific Biosciences of California
Exchange NASDAQ | Headquarters Menlo Park, CA, United States | ||
IPO Launch date 2010-10-27 | CEO, President & Director Mr. Mark Van Oene Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 485 | Website https://www.pacb.com |
Full time employees 485 | Website https://www.pacb.com | ||
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.